Physician profile
Thomas Repko
NPI 1750373403
$3,306.57
in general payments reported to CMS, 2019-2025
18 companies · $649 in 2025
The $649 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $806 · 2020: $196 · 2021: $369 · 2022: $666 · 2023: $572 · 2024: $48.43 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,269.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $648.21 | 2022-2025 | Vyzulta, Miebo |
| Allergan, INC. | $611.05 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $309.80 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $303.03 | 2019-2021 | |
| Oyster Point Pharma, INC. | $291.54 | 2022-2024 | Tyrvaya, Ryzumvi |
| Abbvie INC. | $272.77 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $203.12 | 2019 | |
| Alcon Vision LLC | $190.40 | 2019-2025 | Clareon, Tryptyr |
| Eyevance Pharmaceuticals LLC | $115.81 | 2022 | |
| Dompe US, INC. | $66.28 | 2021-2024 | Oxervate |
| Harrow Eye, LLC | $61.95 | 2025 | Vevye |
| Kala Pharmaceuticals, INC. | $58.36 | 2019-2021 | |
| Carl Zeiss Meditec, INC. | $57.26 | 2021 | |
| Sun Pharmaceutical Industries INC. | $39.41 | 2021-2023 | Cequa |
| Amgen INC. | $27.38 | 2025 | Tepezza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $20.42 | 2025 | Iyuzeh |
| Astellas Pharma US INC | $16.63 | 2023 | Izervay |
| Horizon Therapeutics Plc | $13.15 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Repko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.